Navigation Links
Medgenics' Phase I/II Clinical Trial Now Shows EPODURE Continuous Anemia Treatment Lasting 5 Months in Kidney Disease Patients
Date:3/27/2009

- Results to be presented at Israel Society of Nephrology Conference

- EPODURE safety and efficacy now reach 5 months from single treatment

- Data continue to indicate that Biopump may offer alternative to scores of expensive injections

MISGAV, Israel and LONDON, March 27 /PRNewswire/ -- Medgenics (AIM: MEDG) is pleased to announce that the latest, encouraging results of the Company's ongoing EPODURE Biopump Phase I/II Clinical Trial will be presented at the 45th Conference of the Israeli Society of Nephrology and Hypertension, in Israel on March 27, 2009.

The latest results of the trial show that in the first 2 of the patients treated, the hemoglobin level has now remained continuously in the target range of 10-12 g/dl for more than 5 months following a single EPODURE treatment using the lowest dose of 20 IU/kg/day, thus effectively treating their anemia without receiving any injections of erythropoietin (EPO) during this period. One of the patients received his last EPO injection more than 200 days ago. This is contrasted with the FDA approved standard regimen of thrice weekly EPO injections, in which typical patients would expect to receive up to 85 injections in this timeframe.

A total of 7 patients have now been treated, with 6 patients receiving treatment for more than one month. The seventh patient is the first to receive the higher dose of 40 IU/kg/day, which is double that of the lowest dosage, and the higher dose treatment is proceeding smoothly. There continue to be no adverse events reported in the study. Patient recruitment continues for the higher dose treatment.

The new data will be presented at the conference by Dr. Michal Dranitzki Elhalel, the principal nephrologist of Medgenics' EPODURE Phase I/II clinical trial, currently taking place at the Hadassah Hebrew University Hospital in Jerusalem, Israe
'/>"/>

SOURCE Medgenics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Medgenics Announces Positive Data From Phase I/II Clinical Trial of EPODURE Treatment of Anemia in Chronic Kidney Disease
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
4. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
5. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
8. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
9. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
10. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
11. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Aug. 21, 2014  The board of directors of ... provider of clinical trial imaging solutions, today announced that ... financial officer, effective immediately.  Mr. Groff has held the ... He joined VirtualScopics in January 2006 as an accounting ... "When the board of VirtualScopics asked Jim ...
(Date:8/21/2014)... (NASDAQ: CYBX ) today announced results for the ... 1   Operating results for the first quarter ... 2014, and other achievements, include: , Worldwide net product ... Strong international net sales of $13.2 million, an increase of ... product sales reached a new high of $58.8 million, an ...
(Date:8/20/2014)... Aug. 20, 2014 Northstar Global Business ... after months of hard work from many talented ... Snorenz formulation and package design.  The new formulation ... back into the product due to overwhelming evidence ... effects.  Snorenz Nighttime will also include these vitamins, ...
Breaking Medicine Technology:VirtualScopics, Inc. Names James Groff Chief Financial Officer 2VirtualScopics, Inc. Names James Groff Chief Financial Officer 3VirtualScopics, Inc. Names James Groff Chief Financial Officer 4Cyberonics Reports Fiscal 2015 First Quarter Results 2Cyberonics Reports Fiscal 2015 First Quarter Results 3Cyberonics Reports Fiscal 2015 First Quarter Results 4Cyberonics Reports Fiscal 2015 First Quarter Results 5Cyberonics Reports Fiscal 2015 First Quarter Results 6Cyberonics Reports Fiscal 2015 First Quarter Results 7Cyberonics Reports Fiscal 2015 First Quarter Results 8Cyberonics Reports Fiscal 2015 First Quarter Results 9Cyberonics Reports Fiscal 2015 First Quarter Results 10Cyberonics Reports Fiscal 2015 First Quarter Results 11Cyberonics Reports Fiscal 2015 First Quarter Results 12Cyberonics Reports Fiscal 2015 First Quarter Results 13Cyberonics Reports Fiscal 2015 First Quarter Results 14Cyberonics Reports Fiscal 2015 First Quarter Results 15Cyberonics Reports Fiscal 2015 First Quarter Results 16Northstar completes the first phase of its new retail strategy and prepares to ship reformulated Snorenz with all new packaging 2
... Mettler-Toledo International Inc. (NYSE: MTD ) today ... Life Sciences Conference in New York on Wednesday, September 21, ... webcast of the presentation, visit the investor relations page on ... of the webcast will be available for seven days. ...
... Sept. 14, 2011 Micross Components, a leading ... Deley as General Manager of its US Products ... in product and business development, will play a ... and its offerings to increase market share across ...
Cached Medicine Technology:Micross Components Names Mike Deley as General Manager of US Products & Services Division 2
(Date:8/21/2014)... 2014--Mesenchymal stem cells (MSCs) are present in virtually every ... regeneration after injury. But the theory that MSCs are ... following organ damage, and migrate to the site of ... provide conclusive evidence to resolve the controversy over the ... new study published in Stem Cells and Development ...
(Date:8/21/2014)... effective vaccination, polio is considered nearly eradicated. Each year ... scientists of the University of Bonn, together with colleagues ... that was able to resist the vaccine protection to ... outbreak in the Congo in 2010. The pathogen could ... results appear now in the magazine PNAS . ...
(Date:8/21/2014)... 21, 2014 Glioblastoma Multiforme Therapeutics ... Approaches Target High Unmet Need in Newly Diagnosed ... the Glioblastoma Multiforme (GBM) therapeutics market within the ... Japan. The report provides estimates of market size ... It also covers disease epidemiology, treatment algorithms, treatment ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 One of ... is likely to experience is an increasing adoption of ... the compliance of the patient through their convenient application, ... delivery system is a medical device used for the ... in the nose and paranasal sinus such as allergic ...
(Date:8/21/2014)... Hospital officials, community leaders and elected officials today ... building at Mount Sinai Queens, marking the completion of ... and modernization project. During the event, hospital officials ... Chairman of the nearby Kaufman Astoria Studios, for which ... be named. The project, which began late last ...
Breaking Medicine News(10 mins):Health News:Polio: Mutated virus breaches vaccine protection 2Health News:Asia-Pacific Glioblastoma Multiforme (GBM) Market Size Industry Analysis, Share, Growth, Trends and Forecast to 2020: MarketResearchReports.biz 2Health News:Asia-Pacific Glioblastoma Multiforme (GBM) Market Size Industry Analysis, Share, Growth, Trends and Forecast to 2020: MarketResearchReports.biz 3Health News:Asia-Pacific Glioblastoma Multiforme (GBM) Market Size Industry Analysis, Share, Growth, Trends and Forecast to 2020: MarketResearchReports.biz 4Health News:Asia-Pacific Glioblastoma Multiforme (GBM) Market Size Industry Analysis, Share, Growth, Trends and Forecast to 2020: MarketResearchReports.biz 5Health News:Asia-Pacific Glioblastoma Multiforme (GBM) Market Size Industry Analysis, Share, Growth, Trends and Forecast to 2020: MarketResearchReports.biz 6Health News:Asia-Pacific Glioblastoma Multiforme (GBM) Market Size Industry Analysis, Share, Growth, Trends and Forecast to 2020: MarketResearchReports.biz 7Health News:Intranasal Drug Delivery Market 2014 – 2018 Global Forecasts and Analysis in New Research Report at Sandlerresearch.org 2Health News:Intranasal Drug Delivery Market 2014 – 2018 Global Forecasts and Analysis in New Research Report at Sandlerresearch.org 3Health News:Intranasal Drug Delivery Market 2014 – 2018 Global Forecasts and Analysis in New Research Report at Sandlerresearch.org 4Health News:Intranasal Drug Delivery Market 2014 – 2018 Global Forecasts and Analysis in New Research Report at Sandlerresearch.org 5Health News:“Topping Off” Ceremony Marks Major Milestone in Mount Sinai Queens Construction Project 2Health News:“Topping Off” Ceremony Marks Major Milestone in Mount Sinai Queens Construction Project 3Health News:“Topping Off” Ceremony Marks Major Milestone in Mount Sinai Queens Construction Project 4
... , WASHINGTON, Sept. 9 Former presidential ... care address said Tuesday that he would be listening for ... willing to make to show that his promises of bipartisan ... The chairman of the Campaign for Working Families made the ...
... , , , BOSTON and ... its causes, potential cures, current treatments and strategies for living well ... Macular Degeneration Symposium on September 17. A free public educational program, ... the Barnstable Senior Center, 825 Falmouth Road (Rt. 28) in Hyannis. ...
... FLEMINGTON, N.J., Sept. 9 HCD Research announced ... Barack Obama,s speech on health care reform tonight to obtain ... care reform. , , (Logo: ... HCD Research will conduct the study using its MediaCurves.com(R) website ...
... , , LAKE MARY, ... nation,s largest independent specialty pharmacy providers, was again chosen as ... is the fifth consecutive year that Axium has received this ... Business Journal recognizes the top 100 privately held companies in ...
... , , PRINCETON, N.J., Sept. 9 ... ) today announced the opening of new clinical development offices in Sao ... global footprint with a comprehensive range of services across Latin America. Earlier ... These new sites will support staff in these countries, Central America, and ...
... pandemic may have antiviral properties, scientists say, , WEDNESDAY, Sept. ... sap has components that show great efficacy in killing off ... plant, Ferula assa-foetida , grows throughout Iran, Afghanistan and ... due to its ill-smelling sap. But the researchers note that ...
Cached Medicine News:Health News:Bauer Calls for News of Concrete Compromise from President Obama 2Health News:First Cape Cod Macular Degeneration Symposium To Be Held on September 17 2Health News:First Cape Cod Macular Degeneration Symposium To Be Held on September 17 3Health News:Research Firm will Obtain Americans' Reactions to the President's Speech on Health Care Reform 2Health News:Axium Healthcare Pharmacy, Inc. Has Been Chosen as One of 'Central Florida's Golden 100 Companies' for the Fifth Year in a Row 2Health News:Covance Opens New Clinical Development Offices in Brazil and Mexico 2Health News:Covance Opens New Clinical Development Offices in Brazil and Mexico 3
... The RSV OIA test features a ... your results. Approved for children under age ... provides an answer in just over 15 ... will enable you to decrease costs for ...
The GC OIA test is a rapid assay for the diagnosis of gonorrhea. Thermo solved the challenge of developing a specific rapid assay for Neisseria gonorrhea by using the proprietary ribosomal protein, ...
... A/B test combines performance equivalence to 14-day viral ... or B with a simple, easy-to-use test with ... has all the same procedural steps as our ... you decrease costs for unnecessary ancillary testing, improve ...
... Strep test delivers excellent sensitivity and specificity for ... simple, easy-to-use test that provides an answer in ... you to provide improved patient care with a ... laboratories. Find out what value we bring to ...
Medicine Products: